WADA Prohibited is a recurring topic in our peptide coverage. This hub collects every article tagged WADA Prohibited, newest first, each evidence-graded and tied to real, verifiable sources.
A clinical monograph on HGH Fragment 176-191 — the C-terminal 'lipolytic tail' of growth hormone sold as a fat-loss peptide. No human RCTs, an antilipogenic animal mechanism, and a closely related analogue (AOD-9604) that failed its pivotal obesity trial.
A clinical monograph on the injectable FSH and LH analogs of reproductive medicine — Grade A, FDA-approved biologics validated by large RCTs and a Cochrane meta-analysis of ~9,600 couples, with OHSS and multiple gestation as the headline risks.
A clinical monograph on human chorionic gonadotropin (hCG) — the FDA-approved LH-mimetic hormone used to trigger ovulation and preserve intratesticular testosterone, with the 'hCG diet' debunked and illegal.
A clinical monograph on hexarelin (examorelin) — one of the most potent growth-hormone-releasing peptides. Real human GH-provocation and acute cardiac data (Grade B), preclinical cardioprotection claims (Grade C), and a 2026 status that is unapproved and banned in sport.
A clinical monograph on gonadorelin — synthetic native GnRH used as an HPG-axis diagnostic and as pulsatile pump therapy. Real human efficacy in narrow indications, but the popular TRT-adjunct use is essentially unstudied.
A clinical monograph on GHRP-6 — the first-generation ghrelin-receptor agonist that reliably triggers a growth hormone pulse and a potent appetite surge. Real but small human data, no therapeutic RCTs, and a restricted 2026 legal status.
A clinical monograph on GHRP-2 (pralmorelin) — the ghrelin-receptor agonist approved in Japan as a single-dose GH-deficiency diagnostic. Grade-A acute GH provocation, no chronic-use evidence, and a restrictive 2026 legal status.
A clinical monograph on follistatin and FS-344 — the activin-myostatin trap marketed for muscle growth. Real human signal exists only as small gene-therapy trials; the injectable peptide has no validated efficacy.
A clinical monograph on epithalamin — the bovine pineal-gland peptide extract that is the natural precursor of synthetic epitalon. A provocative single-program human mortality dataset, no independent RCT, and an unsettled 2026 legal status.
A clinical monograph on epitalon (epithalon, AEDG) — the synthetic pineal tetrapeptide marketed as a telomerase-activating geroprotector. Real circadian and cell-culture signals, no Western RCT, and a 2026 FDA inflection point.
A clinical monograph on Pinealon (Glu-Asp-Arg / EDR), the Khavinson ultrashort neuroprotective tripeptide. Reproducible preclinical antioxidant data, no human RCT, and an unapproved 2026 legal status.
A clinical monograph on dihexa — the angiotensin IV-derived nootropic peptide promoted for cognition. Its evidence is preclinical only, its foundational mechanism papers were retracted for fraud, and its clinical prodrug failed an Alzheimer's trial.
A clinical monograph on Cortagen (Ala-Glu-Asp-Pro) — the Khavinson-program 'cytogen' tetrapeptide marketed for nerve repair and neuroprotection. One intriguing rat nerve-regeneration signal, no human RCTs, and an unapproved-research-chemical legal status.
A clinical monograph on CJC-1295 without DAC (Mod GRF 1-29) — the short-acting, pulse-preserving GHRH analog. Solid preclinical pharmacology, no human RCT of the no-DAC molecule, and an unsettled 2026 legal status.
A clinical monograph on CJC-1295 with DAC — the albumin-tethered, long-acting GHRH analog. Small Phase 1 RCTs prove it raises GH and IGF-1 for days (Grade B), but no clinical-outcome trial exists, and it is unapproved and banned in sport.
A clinical monograph on Bronchogen — the lung/bronchial 'bioregulator' tetrapeptide (ADEL/AEDL) from the Khavinson short-peptide program. Promising preclinical biology, zero human efficacy or safety trials, and an unapproved 2026 legal status.
A clinical monograph on the arginate (di-L-arginine) salt of BPC-157 — the same peptide with an arginine counterion. The storage and gastric-acid stability advantage is real; the headline oral-bioavailability claims are unproven marketing.
A clinical monograph on ARA-290 (cibinetide) — the non-erythropoietic EPO-derived peptide with genuine Phase 2 RCT data for small-fiber neuropathy, no Phase 3, and an unapproved, WADA-prohibited 2026 status.
A clinical monograph on Angiotensin-(1-7) / TXA127 (talfirastide) — the effector of the protective ACE2/Mas arm of the renin-angiotensin system. Real human RCTs, a negative COVID-19 trial, and no FDA approval.
A clinical monograph on AOD-9604 — the hGH-fragment fat-loss peptide that completed six human RCTs and largely failed to beat placebo. Strong safety data, a failed pivotal weight-loss trial, and an unsettled 2026 legal status.
WADA Prohibited is a topic our editors cover across the site. This hub aggregates the related, evidence-graded guidance.
This hub updates automatically whenever a new article is tagged WADA Prohibited, so the latest coverage appears first.
Yes. Every article here grades its efficacy claims A-D and cites real, verifiable studies, regulatory documents or trial registries.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.